Orgenesis Stock Book Value Per Share
| ORGSDelisted Stock | USD 1.22 0.31 20.26% |
Orgenesis fundamentals help investors to digest information that contributes to Orgenesis' financial success or failures. It also enables traders to predict the movement of Orgenesis OTC Stock. The fundamental analysis module provides a way to measure Orgenesis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orgenesis otc stock.
Orgenesis |
Orgenesis OTC Stock Book Value Per Share Analysis
Orgenesis' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Orgenesis Book Value Per Share | (3.30) X |
Most of Orgenesis' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orgenesis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Orgenesis is about -3.303 times. This is 94.29% higher than that of the Biotechnology sector and 98.67% lower than that of the Health Care industry. The book value per share for all United States stocks is 100.17% higher than that of the company.
Orgenesis Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orgenesis' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics of similar companies.Orgenesis is currently under evaluation in book value per share category among its peers.
Orgenesis Fundamentals
| Return On Equity | -7.27 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (16.54) % | ||||
| Current Valuation | 23.01 M | ||||
| Shares Outstanding | 4.77 M | ||||
| Shares Owned By Insiders | 21.16 % | ||||
| Shares Owned By Institutions | 4.54 % | ||||
| Number Of Shares Shorted | 56.25 K | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 15.21 X | ||||
| Revenue | 530 K | ||||
| Gross Profit | 36.02 M | ||||
| EBITDA | (54.07 M) | ||||
| Net Income | (64.92 M) | ||||
| Cash And Equivalents | 2.3 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 22.62 M | ||||
| Debt To Equity | 0.64 % | ||||
| Current Ratio | 1.57 X | ||||
| Book Value Per Share | (3.30) X | ||||
| Cash Flow From Operations | (14.84 M) | ||||
| Short Ratio | 2.39 X | ||||
| Earnings Per Share | (8.00) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 146 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 10.07 M | ||||
| Total Asset | 14.55 M | ||||
| Retained Earnings | (176.62 M) | ||||
| Working Capital | (12.33 M) | ||||
| Current Asset | 5.29 M | ||||
| Current Liabilities | 14.92 M | ||||
| Net Asset | 14.55 M |
About Orgenesis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orgenesis's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orgenesis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orgenesis based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |